"id:ID","studyAcronym","studyRationale","studyTitle","id","uuid","studyVersion"
"821","H2Q-MC-LZZT","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","StudyVersion_1","fd570514-88b1-42dd-8500-0e554c9cb3d5","2"
